The mission of the Department of Cancer Biology is to build bridges and teams to drive the best ideas in basic and translational cancer biology and developmental therapeutics to achieve breakthrough advances in the prevention, treatment and cure of cancer. The department faculty are international leaders in brain, colorectal and prostate cancers, leukemia and myeloma, as well as cancer stem cells, mechanisms of DNA damage and repair, and fundamental molecular and cellular processes that impact microbial infections and cancer. Identifying the molecular mechanisms involved in the development and progression of human cancers as well as in normal cellular regulatory processes is our goal, enabling us to achieve our long-term objective of rapidly translating research into strategies that improve patient outcomes.

Department News

 

Advancing the Study of Rare Genetic Disorder Shwachman-Diamond Syndrome
10/16/2020

Dr. Corey and team have successfully genetically engineered a model of zebrafish that mimics Shwachman-Diamond Syndrome pathologies observed in patients, which will help advance research into developing new therapies to treat the disease.

Read More

 

Cleveland Clinic Names Chair of Department of Cancer Biology
08/10/2020

Jae Jung, PhD, a renowned expert in virus-induced cancers and immunology research, will lead Lerner Research Institute’s Department of Cancer Biology and will also serve as director of Cleveland Clinic’s Center for Global and Emerging Pathogens Research.

Read More

 

Targeting WISP1 Shows Early Promise in Treating Glioblastoma in Preclinical Model
06/30/2020

Dr. Bao’s team found that WISP1, a key protein in the Wnt/β-catenin-WISP1 signaling pathway, contributes to glioblastoma progression by maintaining glioma stem cells and tumor-associated macrophages, and that blocking the pathway helped control the disease in preclinical models.

Read More

More News